Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry.
Tsutomu MurakamiYusuke WatanabeNorihito NakamuraMakoto NatsumedaYohei OhnoGaku NakazawaYuji IkariAkihisa KataokaYosuke NishihataKentaro HayashidaMasanori YamamotoJun TanakaKentaro JujoMasaki IzumoKazuki MizutaniKen KozumaPublished in: Heart and vessels (2024)
Short-term treatment with tolvaptan improved HF in patients hospitalized for severe AS, regardless of the presence of AF or SR. After achieving sufficient diuresis, a slight decrease in blood pressure was observed in the AF group, suggesting an appropriate timeframe for safe and effective use of tolvaptan.
Keyphrases
- ejection fraction
- atrial fibrillation
- heart failure
- aortic stenosis
- acute heart failure
- blood pressure
- aortic valve replacement
- end stage renal disease
- left ventricular
- liver failure
- transcatheter aortic valve implantation
- transcatheter aortic valve replacement
- drug induced
- chronic kidney disease
- aortic valve
- left atrial appendage
- left atrial
- early onset
- catheter ablation
- polycystic kidney disease
- oral anticoagulants
- respiratory failure
- intensive care unit
- percutaneous coronary intervention
- metabolic syndrome
- heart rate
- patient reported
- insulin resistance
- blood glucose
- aortic dissection